Adjuvant chemotherapy for gallbladder cancer: Current evidence, controversies, and future directions

doi:10.4240/wjgs.v17.i8.108160

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (352)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-1) series.

Item

Count

PDF

HTML

Tables (1-1)

Sum=132

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

119

Sum=215

Aug 27, 2025 (publication date) through Aug 28, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Gastrointest Surg. Aug 27, 2025; 17(8): 108160
Published online Aug 27, 2025. doi: 10.4240/wjgs.v17.i8.108160

Table 1 Adjuvant chemotherapy regimens for gallbladder cancer

Regimen	Composition	Ref.
Gemcitabine monotherapy	Gemcitabine	Lamarca et al[2], 2022
5-FU/LV	5-FU + LV	Shroff et al[8], 2019
Capecitabine monotherapy	Capecitabine	Shroff et al[8], 2019
Gemcitabine + cisplatin	Gemcitabine + cisplatin	Casak et al[5], 2024
Gemcitabine + oxaliplatin	Gemcitabine + oxaliplatin (GEMOX)	Sharma et al[6], 2025
S-1 monotherapy	Tegafur/gimeracil/oteracil (S-1)	Pavlidis et al[4], 2024

The choice of regimen depends on various factors, including patient tolerance, tumor characteristics, and regional treatment guidelines. 5-FU: 5-fluorouracil; LV: Leucovorin.

Citation: Dai JW, Xing YX, Sun NZ. Adjuvant chemotherapy for gallbladder cancer: Current evidence, controversies, and future directions. World J Gastrointest Surg 2025; 17(8): 108160
URL: https://www.wjgnet.com/1948-9366/full/v17/i8/108160.htm
DOI: https://dx.doi.org/10.4240/wjgs.v17.i8.108160